about
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathologyMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeAutoimmunity: The good, the bad, and the uglySerum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.Clinical Features and Visual Outcomes of Optic Neuritis in Chinese Children.The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.A population-based prospective study of optic neuritis.Observations on the evolving fields of neuroimmunology and neuroinflammation.Pattern Recognition of the Multiple Sclerosis Syndrome.Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder.Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.[Optical coherence tomography in neuromyelitis optica spectrum disorders].Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-EncephalomyelitisCSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
P2860
Q28270042-E7ED9C45-559B-457C-9AEF-A5D0FEBF459EQ30371412-6F9AC8D3-BDDC-49F7-9EE1-62AD9CCE87B8Q36359919-3400F85F-46F1-4ACB-AE96-A74CE9195C1AQ36562604-8287741C-B91D-4F88-9626-FAF4D0131D3BQ37306713-7E0E7489-5FEF-43DC-AC3E-F5B3AFFEFAEBQ40565668-E1C19213-806A-41B0-9EBD-865388D45A51Q42361527-1F2DF2BF-973F-441A-ABCB-FEA22A96E03BQ42694999-C1E897C0-DBA4-4C0D-BD95-9AAF1C8476A3Q43156877-7335DCA4-1B46-4E21-8C10-7DB18A61DB7FQ47096340-5DAD3B8D-218D-4DF5-9A23-040D8A4C0628Q47146682-3BA30724-E98D-49BB-800E-1C103B4F6623Q47163794-60204640-ABCD-4697-A91E-EB34D5DADE8CQ47203404-09018287-C0D5-4957-B65E-FC2A34990436Q47581499-BB7E2217-8F09-480D-9A21-CF32EC946C8AQ50101454-3ABEDFBA-C44C-48CA-BCBB-08FDC6CB67E3Q52668258-E86D9C3A-04B0-4172-996F-2159B8A66641Q58573155-389E227D-79FD-4569-A1B6-EEEC81ECEADAQ58698171-E6A0F781-57F4-4D23-8016-224BCA0F3FCA
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
MOG antibody-associated diseases
@ast
MOG antibody-associated diseases
@en
type
label
MOG antibody-associated diseases
@ast
MOG antibody-associated diseases
@en
prefLabel
MOG antibody-associated diseases
@ast
MOG antibody-associated diseases
@en
P2860
P1476
MOG antibody-associated diseases
@en
P2093
Kevin Rostasy
P2860
P356
10.1212/NXI.0000000000000060
P577
2015-01-22T00:00:00Z